Cancer therapy-focused biotechnology company Onconova Therapeutics Inc. entered into a stock purchase agreement with certain institutional and accredited investors to raise gross proceeds of about $3.4 million.
The company will sell 2,136,193 common shares at $1.60 apiece under the agreement, and the offering is expected to close on or about Sept. 25.
H.C. Wainwright & Co. is the placement agent for the offering.
